Roivant in the news and media
Articles
Roivant Sciences: Coming Nicely To The Boil With Multiple Opportunities
Read the full article hereRoivant's Pipeline & Products Suggest Blockbuster Revenues Await - & Perhaps Significantly More - A Strong, Albeit Higher Risk Investment Opportunity
Roivant Reports Positive Topline Results from ADORING 1, the Second Atopic Dermatitis Phase 3 Trial of VTAMA® (tapinarof) Cream, 1% in Adults and Children as Young as 2 Years Old
Read the full press release here
Finger On The Pulse: The State Of Biopharma Leadership
Read the full article hereIn Vivo asked six biopharma figureheads to share their thoughts on the state of leadership in the life sciences space, exploring the qualities of a great leader, how recent years have shaped this role within the industry and the challenges ahead.
Why Did Pfizer Offload This Potential Mega-Blockbuster Drug?
The Motley FoolLast December, Pfizer (NYSE: PFE) essentially out-licensed its tumor necrosis factor-like ligand 1A (TL1A), PF-06480605 (now RVT-3101), to Roivant Sciences (NASDAQ: ROIV) by forming a new company with the precision drugmaker. Per the terms of the deal Pfizer owns a 25% equity stake in the new company, along with the drug's commercial rights outside of the U.S. and Japan.
Small Molecule Immunotherapy
ForbesIn the wake of the Covid-19 pandemic, there’s one issue that unites hospitals around the globe: health worker burnout. As part of its strategy to help its existing healthcare customers—and woo new ones—Amazon’s cloud division has selected 23 health tech startups from a pool of 500 applications to participate in its latest healthcare accelerator program focused on workforce issues.
With Boehringer Ingelheim’s help, Roivant churns out another Vant to go up against Endeavor, Impact founders.
Endpoints NewsRoivant Sciences has added another branch to its family tree, unveiling Covant Therapeutics with a $10 million upfront commitment from Boehringer Ingelheim to turn up the heat in cancer.
Roivant's Vtama Meets Key Endpoints in Atopic Dermatitis Study >ROIV
MarketWatch
Roivant stock jumps as skin cream Vtama meets main goal of phase 3 eczema trial
Seeking AlphaDermavant Sciences' Vtama cream met the main goal of achieving clearer skin in a phase 3 trial to treat patients as young as two years old, and adults with atopic dermatitis (AD).
Roivant's ulcerative colitis drug from Pfizer shows promising data in early readout
Endpoints NewsRoivant’s ulcerative colitis drug acquired from Pfizer last month has already produced positive data in the first readout of the Phase IIb trial.
Roivant Sciences: 'Fiercely Economic Actor' With Multiple Catalysts
Seeking Alpha
Advancing Medicines That Matter, Matt Gline, CEO, Roivant Sciences
Biotech 2050Matt Gline is the CEO of Roivant Sciences, a company that delivers innovative medicines and technologies to patients by building Vants – nimble, entrepreneurial biotech and healthcare technology companies.
Roivant Is Striving Towards New Standards Of Care
InVivoWith numerous highly anticipated data readouts due over 2023, the spotlight is on Roivant like never before. CEO Matt Gline enlightens In Vivo on the firm’s ‘vant’ subsidiaries, its in-house drug development strategies and the future of its Vtama psoriasis treatment.
Matt Gline wants you to stop thinking of Roivant as a discard company. In 2023, he'll prove it
FierceBiotechMatt Gline has had enough of the quips. Over the course of his seven-year tenure at Roivant Sciences—the last two as CEO—he's fended off what he thinks are condescending characterizations that the “vant” parent company is a discard-reliant pharma and prognostications about the potential of the drugs it works on.
Roivant’s Matt Gline on the hub-and-spoke biotech model and lessons learned from Axovant
BioPharma DiveFailure is part of building a biotech, and Roivant’s CEO says it provides a blueprint for managing scientifically risky bets. Roivant Sciences is hoping for a big year.
JPM23: Roivant CEO says 2023 shaping up to be 'single most exciting year' for new readouts
FierceBiotechMuch has been said about the tumultuousness of the biotech market in 2022 and how the industry and associated innovation will fare in the new year. Roivant Sciences CEO Matt Gline has heard the prognosticating and, at this year’s J.P. Morgan Healthcare Conference, he had a concise message on behalf of his company: We’re moving up.
Five things for pharma marketers to know: Thursday, January 5, 2023
MM+MEli Lilly struck a $55 million deal with Capsida Biotherapeutics to develop gene therapies for central nervous system diseases. Under the agreement, Eli Lilly’s Prevail, which it acquired in 2021 to develop its gene therapy unit, will spearhead early development and Capsida will lead discovery.
Roivant Touts Encouraging Early Data From Ulcerative Colitis Candidate
Yahoo! FinanceRoivant Sciences (NASDAQ: ROIV) announced results from the induction period of the TUSCANY-2 Phase 2b study of RVT-3101 (previously PF-06480605), a once-monthly anti-TL1A antibody for ulcerative colitis.
Roivant reports positive mid-stage data for ulcerative colitis therapy
Seeking AlphaU.K.-based biotech Roivant Sciences (NASDAQ:ROIV) announced Wednesday that its Phase 2b trial for subcutaneous ulcerative colitis therapy RVT-3101 generated statistically significant and clinically meaningful efficacy results at each dose level.
Roivant reveals positive data for IBD drug, intensifying rivalry with Prometheus
BioPharma DiveA race to develop a new kind of treatment for inflammatory bowel disease heated up Wednesday, with the release of positive data for an experimental drug that’s backed by Pfizer and Roivant Sciences.
Quick Takes: Roivant TL1A mAb heading into Phase III in ulcerative colitis
BioCenturyA Phase III showdown between anti-TL1A mAbs for ulcerative colitis is shaping up for 2023 with positive Phase IIb data for RVT-3101 from Roivant Sciences Ltd. (NASDAQ:ROIV) announced less than a month after Prometheus Biosciences Inc. (NASDAQ:RXDX) reported Phase II results for PRA023.
Roivant-Pfizer inflammatory bowel drug hits high expectations in mid-stage study
STATAn experimental inflammatory bowel disease medicine that serves as the basis for a partnership between Roivant Sciences and Pfizer met high expectations for a Phase 2 clinical trial data released.
Roivant Sciences Sees Positive Trial Results for RVT-3101 Antibody
MarketWatch
Fresh from Pfizer deal, Roivant posts 'best-in-class' ulcerative colitis data on rival to Prometheus prospect
FierceBiotechRoivant Sciences has shown its hand in the red-hot race for a new ulcerative colitis market. Weeks after Prometheus Biosciences wowed investors, and with the ink on its deal with Pfizer to enter the race still drying, Roivant has shared phase 2b data it claims position it as a best-in-class contender.